Conatus Pharmaceuticals, Inc. CNAT
We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.
SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.
Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.
GOGO, Inc. GOGO
We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.
Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.
ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.
Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.
Unilife Corp. UNIS
UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.
YORK, Pa., Dec. 2, 2013 /PRNewswire/ – Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.
Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.
Camtek, Ltd. CAMT
Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%
Cheers to anyone who was able to take advantage of those very timely alerts!
IACH, OMED, ETRM, FRO, DGLY, NAVB